Mylan and Heron Settle Patent Dispute: Generic Nausea Drug Entry Delayed Until 2032

Mylan Pharmaceuticals Inc. has reached a settlement agreement with Heron Therapeutics Inc., delaying its entry into the market with a generic anti-nausea drug until 2032. This resolution comes after both companies engaged in patent infringement litigation within the Delaware federal court. The settlement permits Mylan to eventually compete with Heron’s products without further legal contention, ensuring compliance with the concluded patent agreements. For further details on the settlement and its implications, visit the original article on Law360.